PPP1R15A and tauopathy: For example, genetic reduction and pharmacological inhibition of the eIF2α kinase PERK (Moreno et al., 2013; Radford et al., 2015; Scheper and Hoozemans, 2015), overexpression of the eIF2α phosphatase GADD34 (Moreno et al., 2012), or promoting its interaction with eif2B (Halliday et al., 2015) has been shown to be effective in mouse models for different neurodegenerative diseases including tauopathies.